Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | Guard Therapeutics International AB: Guard Therapeutics announces completion of patient enrollment in Phase 2b POINTER study | 46 | GlobeNewswire (Europe) | Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company's ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective... ► Artikel lesen | |
27.05. | Guard Therapeutics International AB: Guard Therapeutics reports positive outcome from second planned safety review in the Phase 2b POINTER study | 56 | GlobeNewswire (Europe) | Guard Therapeutics today announced that an independent Data Safety Monitoring Committee (DSMC) has completed the second and final planned review of safety data from the ongoing Phase 2b clinical trial... ► Artikel lesen | |
25.03. | Guard Therapeutics International AB: Two-thirds of patients enrolled in Guard Therapeutics' Phase 2b POINTER study | 185 | GlobeNewswire (Europe) | Guard Therapeutics announced today that it has reached another key milestone in its ongoing clinical development program. Two-thirds of the approximately 160 planned patients have now been enrolled... ► Artikel lesen | |
14.03. | XFRA CAPITAL ADJUSTMENT INFORMATION - 14.03.2025 | 1.049 | Xetra Newsboard | Das Instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY wird cum Kapitalmassnahme gehandelt am 14.03.2025 und ex Kapitalmassnahme am 17.03.2025 The instrument OBD SE0000514705 OBDUCAT AB B SK 8 EQUITY... ► Artikel lesen | |
10.03. | Guard Therapeutics International AB: The Board of Directors of Guard Therapeutics has resolved on a previously announced rights issue of approximately SEK 150 million | 166 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
GUARD THERAPEUTICS INTERNATIONAL Aktie jetzt für 0€ handeln | |||||
27.02. | Guard Therapeutics International AB: Guard Therapeutics announces positive outcome from first independent safety data review in Phase 2b POINTER study | 126 | GlobeNewswire (Europe) | Guard Therapeutics announced today that an independent Data Safety Monitoring Committee (DSMC) has completed its first planned review of safety data and has recommended that the Phase 2b clinical study... ► Artikel lesen | |
04.09.24 | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Guard Therapeutics International AB | 401 | GlobeNewswire | With effect from September 05, 2024, the subscription rights in Guard
Therapeutics International AB will be traded on First North Growth Market.
Trading will continue up until and including September... ► Artikel lesen | |
02.09.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 02.09.2024 | 588 | Xetra Newsboard | Das Instrument MSPA MA0000011488 ITISSALAT AL-MA. INH.DH 6 EQUITY wird cum Kapitalmassnahme gehandelt am 02.09.2024 und ex Kapitalmassnahme am 03.09.2024 The instrument MSPA MA0000011488 ITISSALAT AL-MA.... ► Artikel lesen | |
29.08.24 | Guard Therapeutics International AB: First patient dosed in Guard Therapeutics' phase 2b study POINTER | 233 | GlobeNewswire (Europe) | Guard Therapeutics today announced that the first patient has been dosed in the phase 2b clinical study POINTER with the drug candidate RMC-035 as a kidney-protective treatment in open-heart surgery.
"It... ► Artikel lesen | |
27.08.24 | Guard Therapeutics International AB: Guard Therapeutics carries out announced rights issue (repair issue) | 200 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
NOVONESIS | 64,32 | +0,22 % | dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion | Press Release
dsm-firmenich completes sale of its stake in Feed Enzymes Alliance to Novonesis for €1.5 billion
Kaiseraugst (Switzerland), Maastricht (Netherlands), June 2, 2025
dsm-firmenich... ► Artikel lesen | |
GENMAB | 193,95 | -0,69 % | Genmab A/S: Genmab Announces Investigational Rinatabart Sesutecan (Rina-S) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL-01 Trial | New data showed that rinatabart sesutecan (Rina-S) 100 mg/m2 led to a confirmed objective response rate (ORR) of 50.0 percent, including two complete responses (CR), and median duration of response... ► Artikel lesen | |
ARBUTUS BIOPHARMA | 2,962 | -2,89 % | Arbutus Biopharma Corporation: Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update | Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S. mRNA-LNP vaccine litigation scheduled for September... ► Artikel lesen | |
MOLECULIN BIOTECH | 0,800 | -100,00 % | Moleculin Biotech, Inc.: Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) | Annamycin delivering better performance 7th line than would be expected even in 2nd line for monotherapy Responders (Stable Disease or Partial Response) after 2 cycles of Annamycin showed improvement... ► Artikel lesen | |
VERICEL | 37,600 | -2,08 % | Canaccord Genuity reiterates Buy rating on Vericel stock with $61 target | ||
SENSEI BIOTHERAPEUTICS | 0,310 | -0,32 % | H.C. Wainwright stuft Sensei Biotherapeutics-Aktie mit "Kaufen" ein | ||
MUSTGROW BIOLOGICS | 0,542 | -5,90 % | MustGrow Biologics Corp.: MustGrow Announces Record Q1-2025 Results: $3.8 Million Revenue, 14.3% Gross Profit Margin, $4.4 Million in Cash and Inventory | Register/View Here: https://us02web.zoom.us/webinar/register/6217478678603/WN_h8uMVWINQsmS3HWF8K59WgPlease join/register at least 5 minutes prior to the call.Questions emailed to info@mustgrow.ca will... ► Artikel lesen | |
BIOXCEL THERAPEUTICS | 1,360 | -100,00 % | BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders ... | DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical... ► Artikel lesen | |
REGENXBIO | 8,300 | -1,78 % | REGENXBIO Inc.: Regenxbio Reports New Positive Functional Data From Phase I/ii Affinity Duchenne Trial Of Rgx-202 | RGX-202 demonstrating consistent evidence of positively changing disease trajectory for Duchenne
All dose level 2 participants exceeded external natural history controls on all... ► Artikel lesen | |
AKEBIA | 3,498 | +0,52 % | Akebia Therapeutics, Inc.: Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology | CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease... ► Artikel lesen | |
FENNEC PHARMACEUTICALS | 6,950 | -6,08 % | Fennec Pharmaceuticals Inc.: Fennec Announces Results of Annual Meeting | RESEARCH TRIANGLE PARK, N.C., June 03, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the "Company") (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy... ► Artikel lesen | |
ZEVRA THERAPEUTICS | 7,600 | -1,94 % | Zevra Therapeutics: Zevra Announces Final Results of 2025 Annual Meeting of Stockholders | Zevra Stockholders Re-Elect Wendy L. Dixon, Ph.D. and Tamara A. Favorito to the Company's Board of Directors Board and Management Reaffirm Commitment to Driving Continued Growth and Progress Against... ► Artikel lesen | |
REVANCE THERAPEUTICS | 3,420 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 07.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 07.02.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 07.02.2025ISIN NameCA09226M1005 BLACK... ► Artikel lesen | |
CORVUS PHARMACEUTICALS | 3,560 | +3,49 % | Corvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3... ► Artikel lesen | |
CARTESIAN THERAPEUTICS | 7,800 | -2,50 % | Cartesian Therapeutics, Inc.: Cartesian Therapeutics Announces New Employment Inducement Grants | FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases... ► Artikel lesen |